Filing Flows › Comparisons › CAPR vs PYXS
Capricor Therapeutics vs Pyxis Oncology: CAPR and PYXS compared
Capricor Therapeutics is the larger company: $11.1M of revenue in its latest quarter (Q4 2024) against $11.0M for Pyxis Oncology (Q4 2025). Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -165.7%.
Where the money goes: CAPR and PYXS
Capricor Therapeutics (CAPR) · Q4 2024
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
Pyxis Oncology (PYXS) · Q4 2025
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Capricor Therapeutics (CAPR) | Pyxis Oncology (PYXS) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q4 2025 |
| Revenue | $11.1M | $11.0M |
| Revenue growth, Y/Y | -8% | — |
| Operating margin | -69.1% | -165.7% |
| Net earnings | −$7.1M | −$18.1M |
| Net margin | -63.9% | -164.0% |
| Operating cash flow | −$14.8M | −$10.4M |
Questions
Which is bigger, Capricor Therapeutics or Pyxis Oncology?
Capricor Therapeutics is the larger company: $11.1M of revenue in its latest quarter (Q4 2024) against $11.0M for Pyxis Oncology (Q4 2025).
Is Capricor Therapeutics or Pyxis Oncology growing faster?
Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -165.7%.
More: Capricor Therapeutics earnings · how Capricor Therapeutics makes money · Pyxis Oncology earnings · how Pyxis Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 26, 2025; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.